Shaaltiel Yoseph (CIK 0001385118)

Latest company ownership

PLX - Protalix BioTherapeutics, Inc.
Role: Executive VP, R&D
Shares held
700,000
Last filed at
Sep 14, 2018
Confidence Score
50.0
2025Q4
Confidence Score History
2007Q4 2025Q4

Recent buy/sell transactions

Exec date Filing date Company Role Signal Confidence Shares % of shares Under plan? Amount (USD)
May 2, 2012 May 4, 2012 Protalix BioTherapeutics, Inc. Executive VP, R&D Sell 5.0 -300,000 -39.28% ✓ $2.1M
Aug 5, 2010 Aug 9, 2010 Protalix BioTherapeutics, Inc. Executive VP, R&D Sell 30.0 -53,027 -6.49% ✓ $371.2K
Jun 21, 2010 Jun 23, 2010 Protalix BioTherapeutics, Inc. Executive VP, R&D Sell 30.0 -52,973 -6.09% ✓ $370.8K
Apr 29, 2010 May 3, 2010 Protalix BioTherapeutics, Inc. Executive VP, R&D Sell 45.0 -12,691 -1.44% ✓ $88.8K
Apr 14, 2010 Apr 16, 2010 Protalix BioTherapeutics, Inc. Executive VP, R&D Sell 55.0 -1,309 -0.15% ✓ $9.2K
Mar 23, 2010 Mar 25, 2010 Protalix BioTherapeutics, Inc. Executive VP, R&D Sell 5.0 -380,000 -30.07% ✓ $2.7M
Oct 15, 2009 Oct 19, 2009 Protalix BioTherapeutics, Inc. Executive VP, R&D Sell 30.0 -100,000 -7.33% ✓ $940.7K
Jul 6, 2009 Jul 8, 2009 Protalix BioTherapeutics, Inc. Executive VP, R&D Sell 30.0 -100,000 -6.83% ✓ $509.4K
May 13, 2009 May 20, 2009 Protalix BioTherapeutics, Inc. Executive VP, R&D Sell 22.5 -30,000 -2.01% ✗ $108.7K
Mar 13, 2009 Mar 13, 2009 Protalix BioTherapeutics, Inc. Executive VP, R&D Sell 36.3 -8,300 -0.55% ✗ $18.1K
Dec 17, 2007 Dec 26, 2007 Protalix BioTherapeutics, Inc. Executive VP, R&D Buy 72.5 +14,900 0.50% ✗ $50.4K
Dec 5, 2007 Dec 12, 2007 Protalix BioTherapeutics, Inc. Executive VP, R&D Buy 68.8 +15,100 0.51% ✗ $47.4K